help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenough, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenough, A.
American Journal of Respiratory and Critical Care Medicine Vol 169. pp. 663-665, (2004)
© 2004 American Thoracic Society


Editorial

Sickle Cell Disease—Pulmonary Complications and a Proinflammatory State?

Anne Greenough, M.D.

Guy's, King's and St. Thomas' School of Medicine King's College London, United Kingdom

Pulmonary complications frequently lead to mortality and morbidity in patients with sickle cell disease. In a multicenter study, more than 20% of the adults suffered fatal pulmonary complications. (1). Lung function abnormalities are present in young children with sickle cell disease (2). Restrictive abnormalities become more prominent with increasing age (2) and even young adults with sickle chronic lung disease have restrictive lung disease with abnormal diffusing capacity and hypoxemia. The development of pulmonary hypertension increases the mortality up to seven fold (3). A major risk factor for sickle chronic lung disease is recurrent episodes of acute chest syndrome (4), which are the leading cause of death and the second most common cause of hospitalization in adults (1, 5).

An important goal is to effectively treat and preferably prevent acute chest syndrome; this will best be achieved by a thorough understanding of its pathophysiology. A proinflammatory state has been suggested to exist in sickle cell disease, which could predispose to acute chest syndrome in response to a trigger such as infection (6). Evidence for this includes a leucocytosis, which, in the absence of infection, is associated with an increased risk of adverse outcome (7). In addition, elevated cytokine levels have been reported. The findings, however, are not consistent; for example, interleukin levels (IL-6, IL-10, and IL-4) were raised only in 78%, 41%, and 13% respectively of steady-state patients (8). Tumor necrosis factor-{alpha} levels have been reported to be raised at baseline, elevation is particularly marked if there is infection (9). IL-8 levels are raised during complications, but results conflicting regarding whether this occurs with vasoocclusive crises (10) or with the acute chest syndrome (11).

In this issue of the Journal (pp. 687–695), Holtzclaw and colleagues (12) provide data to further extend the debate regarding the importance of a possible proinflammatory state and the development of pulmonary complications. They examined transgenic sickle cell and control mice at baseline and after administration of endotoxin lipopolysaccharide. Cytokine and vascular cell adhesion molecule levels in blood and bronchoalveolar lavage fluid, white cell counts, mRNA expression, survival, lung histology and results of a measure of airways obstruction were assessed. At baseline, levels of circulating leucocytes and vascular cell adhesion molecules were elevated in the sickle cell mice. The lack of other significant findings may reflect the small numbers of animals studied, as IL-6 levels are reported raised in transgenic sickle mice (13). In response to the lipopolysaccharide challenge, the sickle cell compared with the control mice had significantly higher serum and bronchoalveolar levels of cytokines (TNF-{alpha}, IL-1ß) and vascular cell adhesion molecules. The microarray analysis identified 413 genes differentially expressed in the sickle cell mice compared with only seven in the controls. Interpretation of those findings, however, awaits reverse transcriptase-PCR validation and detailed pathway analysis of the differential gene expression. The mortality and the measure of airways obstruction were higher in the sickle cell mice, but the lung histology did not differ from that of the control mice. Holtzclaw and colleagues (12) postulate their findings suggest that there is a subclinical proinflammatory response in sickle cell disease and that the enhanced response to an inflammatory insult they demonstrate, could play a role in the increased susceptibility to pulmonary dysfunction. The results are interesting, but do they support their hypothesis?

The trigger used by Holtzclaw (12) was the endotoxin lipopolysaccharide, which is not a common trigger for acute chest syndrome. In a 30-center study (6), specific causes for acute chest syndrome were only identified in 38% of cases, including 27 different infectious pathogens. Common infectious triggers are community organisms; viral infections being important in the winter months. The animals were studied for only four hours post challenge, thus it cannot be determined whether progression to the expected chronic changes of sickle cell disease would occur. The sickle cell mice had a greater mortality, but their lung histology was normal and there were no significant differences in the lung histology of the sickle cell and control mice. The only finding suggesting that the enhanced inflammatory response was associated with pulmonary dysfunction was the higher "airway obstruction" in the sickle mice.

Airway obstruction was assessed indirectly, using a single chamber whole body plethysmograph and measurement of enhanced pause, which incorporates ratios of exhalation to relaxation time and peak inspiratory to peak expiratory flow. Increased enhanced pause results following methacholine challenge have been associated with increased IgE production and eosinophil lung infiltration and inhibited by pretreatment with a ß-agonist (14). The methodology used by the authors, however, makes assumptions that the temperature gradient between the alveolar and chamber air, the breathing pattern, and the lung volume all remain constant (15). Monitoring of the temperature gradient and breathing pattern, however, were not documented and a constant lung volume cannot be guaranteed by a lack of histological change (12).

Because they documented an increase in airway tone without any histological change although with increased cytokine expression, Holtzclaw and colleagues (12) hypothesize that the airways obstruction in sickle cell disease is not typical asthma pathophysiology. Yet, results of uncontrolled studies suggest bronchodilator administration is helpful in acute chest syndrome; in one series (6), a fifth of patients so treated had a positive response. In addition, bronchial hyperreactivity may be common in children with sickle cell disease; being present in 64% of those without a known history of reactive airway disease (16).

In conclusion, the results of the study of Holtzclaw and colleagues (12) support the concept of an exaggerated response to an inflammatory challenge in sickle cell disease. The relationship to the pulmonary complications of sickle cell disease, however, needs to be interpreted with caution. The data should encourage longer-term animal studies and clinically based investigations examining the temporal relationship of changes in cytokine levels and lung function and their responses to treatment. Whether there is link between asthma/bronchial hyperreactivity and the pulmonary complications of sickle cell disease also merits further investigation. If such a link does exist, aggressive administration of antiasthma therapy might improve outcome.

FOOTNOTES

Conflict of Interest Statement: A.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this editorial.

REFERENCES

  1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–1644.[Abstract/Free Full Text]
  2. Sylvester K, Patey RA, Dick M, Rafferty GF, Rees D, Thein SL, Greenough A. Pulmonary function abnormalities in children with sickle cell disease. Thorax 2004;59:67–70.[Abstract/Free Full Text]
  3. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994;74:626–628.[CrossRef][Medline]
  4. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease; prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988;67:66–76.[Medline]
  5. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643–649.[Abstract/Free Full Text]
  6. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855–1865.[Abstract/Free Full Text]
  7. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83–89.[Abstract/Free Full Text]
  8. Taylor SC, Shacks SJ, Qu A, Wiley P. Type 2 cytokine serum levels in healthy sickle cell disease patients. J Natl Med Assoc 1997;89:753–757.[Medline]
  9. Kuvibidila S, Gardner R, Ode D, Yu L, Lane G, Warrier RP. Tumor necrosis factor alpha in children with sickle cell disease in stable condition. J Natl Med Assoc 1997;89:609–615.[Medline]
  10. Duits AJ, Schnog JB, Lard LR, Saleh AW, Rojer RA. Elevated IL-8 levels during sickle cell crisis. Eur J Haematol 1998;61:302–305.[Medline]
  11. Abboud MR, Taylor EC, Habib D, Dantzler-Johnson T, Jackson SM, Xu F, Laver J, Ballas SK. Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease. Br J Haematol 2000;111:482–490.[CrossRef][Medline]
  12. Holtzclaw JD, Jack D, Aguayo SM, Eckman JR, Roman J, Hsu LL. Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice. Am J Respir Crit Care Med 2004;169:687–695.[Abstract/Free Full Text]
  13. Belcher JD, Bryant CJ, Nguyen J, Bowlin PR, Kielbik MC, Bischof JC, Hebbel RP, Vercellotti GM. Transgenic sickle mice have vascular inflammation. Blood 2003;101:3953–3959.[Abstract/Free Full Text]
  14. Hamelmann E, Schwarze J, Takeda L, Oshiba A, Larsen GL, Irvin CG. Gelfand EW. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997;156:766–775.[Abstract/Free Full Text]
  15. Lundblad LK, Irvin CG, Adler A, Bates JH. A reevaluation of the validity of unrestrained plethysmography in mice. J Appl Physiol 2002;93:1198–1207.[Abstract/Free Full Text]
  16. Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr 1997;131:278–283.[CrossRef][Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenough, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenough, A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society